<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36759402</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Categorization of patients with systemic lupus erythematosus using disease activity, patient-reported outcomes, and transcriptomic signatures.</ArticleTitle><Pagination><StartPage>1555</StartPage><EndPage>1563</EndPage><MedlinePgn>1555-1563</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06525-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Patients with systemic lupus erythematosus (SLE) display symptoms that are not always related to disease activity and may distort clinical trial results. Recently, a clinical categorization based on the presence of type 1 (inflammatory manifestations) and/or type 2 (widespread pain, fatigue, depression) symptoms has been proposed in SLE. Our aim was to develop a type 2 score derived from the Short-Form health survey (SF-36) to categorize SLE patients and to compare immunological and transcriptomic profiles between groups.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Seventeen items from the SF-36 were selected to build a type 2 score for 50 SLE patients (100 visits; LUPUCE cohort), and the SLEDAI was used to define type 1 symptoms. Patients were categorized into four groups: minimal (no symptoms), type 1, type 2, and mixed (both type 1 and type 2 symptoms). Clinical, immunological, and transcriptomic profiles were compared between the groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Type 2 scores ranged from 0 to 31, with a cutoff value of 14 (75th percentile). The sample categorization was minimal in 39%, type 1 in 37%, and type 2 in 9%, and mixed in 15%. Type 2 patients were older than minimal patients and had a longer disease duration than type 1 and mixed patients. Immunological data and modular interferon signatures did not differ between the groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with SLE can be categorized into four clinical groups using the SLEDAI score and our SF-36-derived type 2 score. This categorization is non-redundant with immunological or transcriptomic profiles and could prove useful to stratify patients in clinical trials. Key Points &#x2022; A score derived from selected items of the SF-36 can be used to identify SLE patients with type 2 symptoms according to the Duke University categorization. &#x2022; Using the SLEDAI and this type 2 score, SLE patients can be categorized into four clinical groups. &#x2022; This categorization is not related to immunological activity or blood transcriptome profiles (and not to the interferon signature in particular). &#x2022; This categorization could be useful in the daily care of patients as well as in clinical trials, for upstream patient stratification or for the interpretation of results.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arcani</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>M&#xe9;decine Interne Et Th&#xe9;rapeutique, H&#xf4;pital de La Timone, AP-HM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C2VN, INRAe, INSERM, Aix Marseille Univ, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jouve</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Service Evaluation M&#xe9;dicale, H&#xf4;pital de La Conception, AP-HM, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiche</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>M&#xe9;decine Interne, H&#xf4;pital Europ&#xe9;en, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jourde-Chiche</LastName><ForeName>No&#xe9;mie</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9315-1577</Identifier><AffiliationInfo><Affiliation>C2VN, INRAe, INSERM, Aix Marseille Univ, Marseille, France. noemie.jourde@ap-hm.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de N&#xe9;phrologie Et Transplantation R&#xe9;nale, H&#xf4;pital de La Conception, AP-HM, 147 Boulevard Baille, 13005, Marseille, France. noemie.jourde@ap-hm.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AORC 2008 2009-04</GrantID><Agency>Assistance Publique - H&#xf4;pitaux de Marseille</Agency><Country/></Grant><Grant><GrantID>SHS5-MR - H20171206</GrantID><Agency>Fondation Maladies Rares</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Health-related quality of life</Keyword><Keyword MajorTopicYN="N">Interferon signature</Keyword><Keyword MajorTopicYN="N">SLEDAI</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Transcriptomic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>9</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36759402</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06525-8</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06525-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tektonidou MG, Lewandowski LB, Hu J et al (2017) Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 76:2009&#x2013;2016. https://doi.org/10.1136/annrheumdis-2017-211663</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211663</ArticleId><ArticleId IdType="pubmed">28794077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiani AN, Petri M (2010) Quality-of-life measurements versus disease activity in systemic lupus erythematosus. Curr Rheumatol Rep 12:250&#x2013;258. https://doi.org/10.1007/s11926-010-0114-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-010-0114-1</ArticleId><ArticleId IdType="pubmed">20586000</ArticleId></ArticleIdList></Reference><Reference><Citation>Devilliers H, Amoura Z, Besancenot J-F et al (2015) Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology (Oxford) 54:940&#x2013;949. https://doi.org/10.1093/rheumatology/keu410</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu410</ArticleId><ArticleId IdType="pubmed">25361539</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleanthous S, Tyagi M, Isenberg DA, Newman SP (2012) What do we know about self-reported fatigue in systemic lupus erythematosus? Lupus 21:465&#x2013;476. https://doi.org/10.1177/0961203312436863</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203312436863</ArticleId><ArticleId IdType="pubmed">22345120</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider M (2016) Pitfalls in lupus. Autoimmun Rev 15:1089&#x2013;1093. https://doi.org/10.1016/j.autrev.2016.07.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2016.07.033</ArticleId><ArticleId IdType="pubmed">27491566</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Gavand PE, Voll R et al (2019) Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature. Rheumatology (Oxford) 58:987&#x2013;996. https://doi.org/10.1093/rheumatology/key398</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key398</ArticleId><ArticleId IdType="pubmed">30597077</ArticleId></ArticleIdList></Reference><Reference><Citation>Moazzami M, Strand V, Su J, Touma Z (2021) Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years. Lupus 961203320983892. https://doi.org/10.1177/0961203320983892</Citation></Reference><Reference><Citation>Moon S-J, Kang KY, Kwok S-K et al (2018) Differences in quality of life determinants according to the presence of fibromyalgia in middle-aged female patients with systemic lupus erythematosus: a multicenter, cross-sectional, single-ethnicity cohort. Int J Rheum Dis 21:1173&#x2013;1184. https://doi.org/10.1111/1756-185X.13320</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13320</ArticleId><ArticleId IdType="pubmed">29879313</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Shah NP, Mudano AS (2021) Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev 2:CD010668. https://doi.org/10.1002/14651858.CD010668.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD010668.pub2</ArticleId><ArticleId IdType="pubmed">33631841</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS, Clowse MEB, Criscione-Schreiber LG, Rogers JL (2019) A novel system to categorize the symptoms of systemic lupus erythematosus. Arthritis Care Res (Hoboken) 71:735&#x2013;741. https://doi.org/10.1002/acr.23794</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23794</ArticleId><ArticleId IdType="pubmed">30354033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JL, Eudy AM, Pisetsky D et al (2021) Using clinical characteristics and patient-reported outcome measures to categorize systemic lupus erythematosus subtypes. Arthritis Care Res (Hoboken) 73:386&#x2013;393. https://doi.org/10.1002/acr.24135</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24135</ArticleId><ArticleId IdType="pubmed">31909888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F, Clauw DJ, Fitzcharles M-A et al (2016) 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 46:319&#x2013;329. https://doi.org/10.1016/j.semarthrit.2016.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2016.08.012</ArticleId><ArticleId IdType="pubmed">27916278</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiche L, Jourde-Chiche N, Whalen E et al (2014) Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 66:1583&#x2013;1595. https://doi.org/10.1002/art.38628</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38628</ArticleId><ArticleId IdType="pubmed">24644022</ArticleId><ArticleId IdType="pmc">4157826</ArticleId></ArticleIdList></Reference><Reference><Citation>Seguier J, Jouve E, Bobot M et al (2020) Paradoxical association between blood modular interferon signatures and quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford) 59:1975&#x2013;1983. https://doi.org/10.1093/rheumatology/kez541</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez541</ArticleId><ArticleId IdType="pubmed">31776548</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourde-Chiche N, Whalen E, Gondouin B et al (2017) Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology (Oxford) 56:477&#x2013;487. https://doi.org/10.1093/rheumatology/kew439</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew439</ArticleId><ArticleId IdType="pubmed">28031441</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazier JE, Harper R, Jones NM et al (1992) Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 305:160&#x2013;164. https://doi.org/10.1136/bmj.305.6846.160</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.305.6846.160</ArticleId><ArticleId IdType="pubmed">1285753</ArticleId><ArticleId IdType="pmc">1883187</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau R, Hong S, Cantarel B et al (2016) Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165:551&#x2013;565. https://doi.org/10.1016/j.cell.2016.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.03.008</ArticleId><ArticleId IdType="pubmed">27040498</ArticleId><ArticleId IdType="pmc">5426482</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopman WM, Harrison MB, Coo H et al (2009) Associations between chronic disease, age and physical and mental health status. Chronic Dis Can 29:108&#x2013;116</Citation><ArticleIdList><ArticleId IdType="doi">10.24095/hpcdp.29.3.03</ArticleId><ArticleId IdType="pubmed">19527569</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Mertz P, Amoura Z et al (2020) Patterns of fatigue and association with disease activity and clinical manifestations in systemic lupus erythematosus. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keaa671</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa671</ArticleId><ArticleId IdType="pubmed">33280012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovejero T, Sadones O, S&#xe1;nchez-Fito T, et al (2020) Activation of transposable elements in immune cells of fibromyalgia patients. Int J Mol Sci 21: https://doi.org/10.3390/ijms21041366</Citation></Reference><Reference><Citation>Dolcino M, Tinazzi E, Puccetti A, Lunardi C (2020) Gene expression profiling in fibromyalgia indicates an autoimmune origin of the disease and opens new avenues for targeted therapy. J Clin Med 9: https://doi.org/10.3390/jcm9061814</Citation></Reference><Reference><Citation>Marcellin P, Lau GKK, Zeuzem S et al (2008) Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 28:477&#x2013;485. https://doi.org/10.1111/j.1478-3231.2008.01696.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2008.01696.x</ArticleId><ArticleId IdType="pubmed">18339074</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond WD, Eilertsen G&#xd8;, Shanmugakumar S, Nossent JC (2019) The impact of cytokines on the health-related quality of life in patients with systemic lupus erythematosus. J Clin Med 8: https://doi.org/10.3390/jcm8060857</Citation></Reference><Reference><Citation>Chiche L, Jourde-Chiche N, Cornec D (2020) Should we finally consider the biopsychosocial model in systemic autoimmune diseases? Arthritis Rheumatol. https://doi.org/10.1002/art.41582</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41582</ArticleId></ArticleIdList></Reference><Reference><Citation>Izadi Z (2020) Health-related quality of life measures in adult systemic lupus erythematosus. Arthritis Care Res (Hoboken) 72(Suppl 10):577&#x2013;592. https://doi.org/10.1002/acr.24245</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24245</ArticleId><ArticleId IdType="pubmed">33091273</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand V, Simon LS, Meara AS, Touma Z (2020) Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. Lupus Sci Med 7: https://doi.org/10.1136/lupus-2019-000373</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>